Related Experiment Video

Updated: Jun 15, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

S Leskelä1, C Jara, L J Leandro-García

  • 1Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

The Pharmacogenomics Journal
|March 10, 2010
PubMed

Insights

Genetic variations in paclitaxel metabolism influence neurotoxicity risk. Specific CYP2C8 and CYP3A5 gene variants impact paclitaxel-induced nerve damage, suggesting personalized therapy potential.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Neuroscience

Background:

  • Paclitaxel neurotoxicity is a major dose-limiting side effect with significant inter-individual variability.
  • The molecular basis for this variability in paclitaxel-induced neurotoxicity is largely unknown.
  • Understanding genetic factors influencing paclitaxel metabolism and clearance is crucial for improving treatment outcomes.

Purpose of the Study:

  • To investigate the association between genetic polymorphisms in paclitaxel elimination pathways and the risk of neurotoxicity.
  • To identify specific gene variants that predict paclitaxel neurotoxicity in cancer patients.
  • To explore the role of drug metabolism and transport genes in paclitaxel-induced nerve damage.

Main Methods:

  • Genotyping of 13 polymorphisms in key paclitaxel metabolizing enzymes (CYP2C8, CYP3A4, CYP3A5) and transporters (OATP1B1, OATP1B3, P-glycoprotein) in 118 Spanish cancer patients.
  • Statistical analysis adjusting for age and treatment schedule to determine associations between genotypes and neurotoxicity.
  • Calculation of Hazard Ratios (HR) and 95% Confidence Intervals (CI) to quantify risk and protection.

Main Results:

  • CYP2C8 Haplotype C and CYP3A5*3 variants were associated with protection against neurotoxicity (HR=0.55, P=0.014 and HR=0.51, P=0.012).
  • The CYP2C8*3 variant was linked to an increased risk of neurotoxicity (HR=1.72, P=0.032).
  • Alleles increasing paclitaxel metabolism correlated with higher neurotoxicity risk (overall HR=1.64, P=0.0003), suggesting a role for metabolites.

Conclusions:

  • Genetic variations in CYP2C8 and CYP3A5 significantly influence paclitaxel neurotoxicity risk.
  • Incorporating pharmacogenetic data may enable personalized paclitaxel dosing to minimize neurotoxic events.
  • Further validation in independent patient cohorts is warranted to confirm these findings.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...